Global Newborn Screening Market is set to grow at a 6-8% CAGR by 2027 - SCIEX, Agilent, Bio-Rad, Covidien, GE, PerkinElmer, Masimo, Trivitron, Labsystems Diagnostics Oy, LifeCell, Archer DX

Newborn screening aims to identify infants at risk of genetic, hormonal and metabolic medical conditions. These screens are used to confirm a diagnosis and allow for early intervention in the hope of prevention or amelioration of the disease. These tests are most commonly performed for conditions which are not evident in the neonatal period but are likely to be treatable with early intervention.

Commonly covered medical conditions are congenital hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, galactosemia, tyrosinemia type I, sickle cell anaemia, G6PD-Deficiency, hearing problems (congenital deafness) and congenital heart problems. These are tested through three standard methods: Blood spot, hearing test and pulse oximetry.

Increasing Population, Growing Cases of Birth Defects and Favourable Government Initiatives are some of the key drivers responsible for the growth of Newborn Screening Market

The global population is projected to grow to 9.7 billion people by 2050 from 8 billion in 2022 and enriching access to primary care (evidenced by the global improvements in life expectancy from 46.5 in 1950 to 71 in 2021) are the prime factors driving the growth of the newborn screening market.

Globally, an estimated 8 million newborns are born with a birth defect every year. As per CDC, birth defects impact one in every 33 babies (about 3% of all babies) born in the United States each year. In the WHO, South-East Asia Region, between 2010 and 2019, birth defects increased as a proportion of child mortality in the region, from 6.2% to 9.2%. The common birth defects are heart defects, neural tube defects and Down syndrome, among others. These can be caused by one or more genetic, infectious, nutritional or environmental factors. To curb the growing birth defects, health organizations across the world are taking essential actions to prevent, detect, manage and care for birth defects.

An Increasing Application of Next-Generation Sequencing Is Projected to Drive the Newborn Screening Market in Developed Countries

Next-Generation Sequencing approaches are slowly being adopted in hospital settings for usage in newborn screening for rare genetic disorders. The cost of sequencing whole exomes has fallen dramatically since its invention and continues to decline - in US, bioinformatics companies can provide sequencing for USD500-USD900. Pilot studies are being conducted in USA, UK, China and many other countries into the suitability for the global use of NGS technology in newborn screening programmes as well as in neonatal wards.

Aggressive Growth Strategies Adopted by the Key Market Players to Establish Their Strong Foothold in the Newborn Screening Market

The majority of commonly performed tests are well established - companies are growing their manufacturing capacity or engaging in M&A activities to strengthen their current market position in newborn screening market:
• In August 2022, Perkin Elmer sold off its Applied, Food and Enterprise Services businesses, and entered into a definitive agreement with New Mountain Capital, L.L.C. to sell off its assets for a total compensation of USD 2.45 billion.
• In August 2022, Triviton Healthcare opened a new R&D and manufacturing facility for chemical-based assays in India. The new center will have provisions to manufacture >300 million RT-PCR kits and >100 million for ELISA, CLIA, NBS and other common diagnostic kits.

China Is Projected to Hold the Largest Share of the Newborn Screening Market - Followed by North America

While China is the largest newborn screening market - 9.56 million babies were born in China in 2022, down from 17.86 million in 2016. Approximately, 93% of newborns are reported to undergo screening in China - the availability of the various range of tests available between urban and rural regions. The penetration of newborn screening in China is poised to grow in the upcoming years due to government initiatives, an increasing number of newborn screening centers and establishment of well-developed newborn screening network system. The Chinese government recognizes newborn screening as a public health project and by the end of 2018, there were ~238 newborn screening centers in China mainland with screening rates exceeding 97.5%. China newborn screening has established a complete network system, from sample collection and delivery, laboratory testing, results reporting, clinical diagnosis to follow-up which has also played a very crucial role in its penetration. Meanwhile, India has become the most populous nation on earth - ~23 million babies were born in 2022, however presently there is no active national NBS programme in India.

Competitive Landscape Analysis: Newborn Screening Market

The global newborn screening market is marked by the presence of well-established and emerging market players such as SCIEX, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Covidien Plc, GE Healthcare, PerkinElmer, Inc., Masimo Corporation, Natus Medical Incorporated, Trivitron Healthcare, Waters Corporation, Labsystems Diagnostics Oy, LifeCell International Pvt.Ltd, Archer DX.

Get Detailed Insights on Newborn Screening Market with a Sample Report Copy @ https://meditechinsights.com/newborn-screening-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.